Compare VSH & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSH | ELVN |
|---|---|---|
| Founded | 1962 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 1994 | 2020 |
| Metric | VSH | ELVN |
|---|---|---|
| Price | $22.43 | $46.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $38.67 | ★ $74.33 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 69.57 | 3.17 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $3,069,048,000.00 | N/A |
| Revenue This Year | $21.51 | N/A |
| Revenue Next Year | $15.23 | N/A |
| P/E Ratio | $39.78 | ★ N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $12.49 | $14.79 |
| 52 Week High | $69.47 | $62.32 |
| Indicator | VSH | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 49.64 |
| Support Level | $21.42 | $44.18 |
| Resistance Level | $30.19 | $46.96 |
| Average True Range (ATR) | 2.10 | 2.47 |
| MACD | -0.11 | -0.17 |
| Stochastic Oscillator | 9.22 | 25.69 |
Vishay Intertechnology Inc provides a broad product portfolio of discrete semiconductors and passive electronic components to original equipment manufacturers and distributors. These products are found in industrial, computing, automotive, consumer, telecommunications, power supplies, military, aerospace, and medical markets and serve customer all over the world. Its product segments consist of two general classes: semiconductors and passive components. The company's operating segment includes metal oxide semiconductor field-effect transistors, diodes, optoelectronic components, resistors, inductors, and capacitors. Revenue mainly comes from resistors, which are basic components used in all forms of electronic circuitry to adjust and regulate levels of voltage and current.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.